Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Released Nov 9, 2023, after the close
10-Q filed Nov 9, 2023, 40 days after period end · 0001410578-23-002307
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $257.61K | $999.57K | — | $0.00 |
| Net Income | -$2.98M | -$6.92M | -$12.43M | -$7.37M |
| EPS Diluted |
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
| -$0.34 |
| -$0.83 |
| -$0.15 |
| -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
